Literature DB >> 20382064

Virus therapy for bladder cancer.

James Burke1.   

Abstract

Approximately 50,000 cases of superficial bladder cancer are diagnosed annually in the United States. Immunotherapy utilizing intravesical BCG is the most effective standard therapy for superficial transitional cell carcinoma of the bladder. Based on ease of administration, limited systemic dissemination, and the demonstrated activity of immunotherapy, superficial bladder cancer is an excellent target for virus based gene and immunotherapy. Thus far, clinical trials of virus therapy for bladder cancer have yielded mixed results. In this paper the results of several virus based clinical trials for bladder cancer are reviewed. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20382064     DOI： 10.1016/j.cytogfr.2010.02.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN： 1359-6101            Impact factor:   7.638


  12 in total

1.  Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.

Authors:  Fang Wang; Zhiping Wang; Hongwei Tian; Meijiao Qi; Zhenxing Zhai; Shuwen Li; Renju Li; Hongjuan Zhang; Wenyun Wang; Shenjun Fu; Jianzhong Lu; Ronald Rodriguez; Yinglu Guo; Liqun Zhou
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

2.  Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer.

Authors:  C-S Lu; J-L Hsieh; C-Y Lin; H-W Tsai; B-H Su; G-S Shieh; Y-C Su; C-H Lee; M-Y Chang; C-L Wu; A-L Shiau
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

3.  Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.

Authors:  Z Zhai; Z Wang; S Fu; J Lu; F Wang; R Li; H Zhang; S Li; Z Hou; H Wang; R Rodriguez
Journal:  Gene Ther       Date:  2012-01-05       Impact factor: 5.250

4.  Multiorientation Simultaneous Computation of Back-Projection CT Image Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.

Authors:  Kaiyan Hu; Jianping Zhu; Pei Li; Lili Ying
Journal:  Comput Math Methods Med       Date:  2022-06-28       Impact factor: 2.809

5.  Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell.

Authors:  Conghui Han; Lin Hao; Meng Chen; Jianpeng Hu; Zhenduo Shi; Zhiguo Zhang; Bingzheng Dong; Yu Fu; Changsong Pei; Yongping Wu
Journal:  Tumour Biol       Date:  2013-05-19

6.  Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer.

Authors:  Helen Gosnell; Laura M Kasman; Thrimoorthy Potta; Lucas Vu; Elizabeth Garrett-Mayer; Kaushal Rege; Christina Voelkel-Johnson
Journal:  J Control Release       Date:  2013-12-24       Impact factor: 9.776

Review 7.  Oncolytic virotherapy for urological cancers.

Authors:  Zahid Delwar; Kaixin Zhang; Paul S Rennie; William Jia
Journal:  Nat Rev Urol       Date:  2016-05-24       Impact factor: 14.432

Review 8.  [YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].

Authors:  P S Holm; M Retz; J E Gschwend; R Nawroth
Journal:  Urologe A       Date:  2016-03       Impact factor: 0.639

Review 9.  Immunotherapy for bladder cancer.

Authors:  Oliver Fuge; Nikhil Vasdev; Paula Allchorne; James Sa Green
Journal:  Res Rep Urol       Date:  2015-05-04

10.  Efficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancer.

Authors:  Peng Huang; Chao Ma; Peng Xu; Kai Guo; Abai Xu; Chunxiao Liu
Journal:  Exp Ther Med       Date:  2014-11-11       Impact factor: 2.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.